ArticleNeuropsychiatric disease and treatment2026
Clinical Practice Recommendations for Switching from Once-Monthly to Longer-Interval Paliperidone Palmitate Injectable in Schizophrenia Patients: A Modified Delphi Study in China.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Schizophrenia is a chronic mental disorder with substantial socioeconomic burden. Long-acting injectable antipsychotics (LAIs) demonstrate superior efficacy over oral antipsychotics in reducing relapse and improving adherence. Switching from short-interval LAIs (such as paliperidone palmitate one-month formulation, PP1M) to longer-intervals LAIs (like paliperidone palmitate three-month and six-month formulations) offers additional benefits to disease outcome. This modified Delphi study aimed to explore clinical consensus on switching strategies to longer-interval LAIs. Patients and Methods: A steering committee of six psychiatrists experienced LAIs treatment in schizophrenia guided questionnaire design and consensus alignment. Thirteen panelists participated in two Delphi rounds. A targeted literature review (TLR) was conducted to generate key topics, preliminary statements and open-ended questions for steering committee interviews. A total of 37 statements were finalized for Delphi. Two Delphi rounds were conducted via one-on-one interviews (Nov-Dec 2024). Each statement was rated following a nine-point Likert scale. Measures of central tendency and variation were calculated. Consensus levels were categorized as "Strong/Moderate/Nearing/No Consensus". Qualitative analyses were performed to refine statements. A final virtual meeting with steering committee confirmed consensus. Results: In the two Delphi rounds, 35 statements reached strong consensus, one moderate consensus, and one nearing consensus. After reviewed by the six steering committee experts, four semantically statements were removed, yielding a final set of 33 consensus statements. Intraclass correlation coefficient improved from 0.674 to 0.751. Conclusion: Final consensus was reached on 33 statements across five domains: clinical necessity, target patient populations, switching strategy, long-term disease management, factors influencing treatment willingness. It presents the first expert consensus in China on longer-interval LAIs usage in schizophrenia, offering evidence-informed guidance for patient selection, switching strategies and long-term disease management to promote standardized clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.